MBX · Mbx Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | $18.47M | - | $19.27M | $17.72M | $11.05M | - | $9.07M |
| SG&A | $8.79M | - | $4.66M | $2.26M | $2.27M | - | $2.87M |
| Total Operating Expenses | $27.27M | - | $23.93M | $21.80M | $13.31M | - | $10.95M |
| D&A | $64.0K | - | $100.0K | $100.0K | $48.0K | - | $100.0K |
| Operating Income | ($27.27M) | - | ($23.93M) | ($16.66M) | ($13.31M) | - | ($10.95M) |
| Interest Expense | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - |
| Net Income | ($23.52M) | - | ($21.62M) | ($19.41M) | ($23.88M) | - | ($10.16M) |
| EPS - Basic | ($0.50) | - | ($0.63) | ($0.58) | ($10.26) | - | ($9.40) |
| EPS - Diluted | ($0.50) | - | ($0.63) | ($0.58) | ($10.26) | - | ($9.40) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $45.21M | $75.29M | $223.13M | $39.78M | $29.90M | $49.35M | $132.87M |
| Accounts Receivable | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - |
| Accounts Payable | $6.97M | $2.98M | $3.77M | $5.76M | $4.25M | $5.33M | $5.00M |
| Current Assets | $448.54M | $381.54M | $397.50M | $229.19M | $244.28M | $267.29M | $83.47M |
| Total Assets | $452.70M | $385.14M | $400.08M | $231.52M | $245.93M | $268.54M | $282.40M |
| Current Liabilities | $14.57M | $15.49M | $12.06M | $11.76M | $10.48M | $11.05M | $10.92M |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | $14.95M | $15.92M | $12.54M | $12.28M | $10.50M | $11.09M | $11.03M |
| Stockholders' Equity | $437.76M | $369.22M | $387.54M | $219.24M | $235.42M | $257.44M | ($97.89M) |
| Retained Earnings | ($247.99M) | ($224.48M) | ($202.41M) | ($180.80M) | ($161.38M) | ($137.50M) | ($75.58M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($20.21M) | - | - | - | ($10.71M) | - | - |
| Investing Cash Flow | ($97.10M) | - | - | - | $15.43M | - | - |
| Financing Cash Flow | $87.44M | - | - | - | $183.0K | - | - |
| CapEx | $437.0K | - | - | - | $273.0K | - | - |
| Free Cash Flow | ($20.64M) | - | - | - | ($10.98M) | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | 0.88 | - | - | - | 0.46 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | -5.2% | - | -5.4% | -8.4% | -9.7% | - | -3.6% |
| Return on equity | -5.4% | - | -5.6% | -8.9% | -10.1% | - | 10.4% |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 30.79 | 24.62 | 32.95 | 19.50 | 23.31 | 24.19 | 7.64 |
| Quick ratio | 30.79 | 24.62 | 32.95 | 19.50 | 23.31 | 24.19 | 7.64 |
| Cash ratio | 3.10 | 4.86 | 18.50 | 3.38 | 2.85 | 4.47 | 12.17 |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - |
| Equity multiplier | 1.03 | 1.04 | 1.03 | 1.06 | 1.04 | 1.04 | -2.89 |
| Liabilities / Assets | 0.03 | 0.04 | 0.03 | 0.05 | 0.04 | 0.04 | 0.04 |
| Efficiency | |||||||
| Asset turnover | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | 3.2x | - | 1.5x | 0.1x | 0.0x | - | - |
| P / S | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -104.8% | - | -118.6% | - | - | - | - |
| Net income growth (YoY) | 1.5% | - | -112.7% | - | - | - | - |
| EPS growth (YoY) | 95.1% | - | 93.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | -88.0% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | 85.9% | 43.4% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing MBX Biosciences against the 5 most active filers in the same SIC group.